CO4970731A1 - Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp - Google Patents
Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fpInfo
- Publication number
- CO4970731A1 CO4970731A1 CO98051818A CO98051818A CO4970731A1 CO 4970731 A1 CO4970731 A1 CO 4970731A1 CO 98051818 A CO98051818 A CO 98051818A CO 98051818 A CO98051818 A CO 98051818A CO 4970731 A1 CO4970731 A1 CO 4970731A1
- Authority
- CO
- Colombia
- Prior art keywords
- ring
- alkyl
- aliphatic ring
- heteroaromatic
- heteroalkyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se relaciona con un compuesto quetiene la extructura:donde (a) R1 es CO2 H, C(O)NHOH, CO2 R5 , CH2 OH, S(O)2 R5 , C(O)NHR5 , C(O)NHS(O)2 R5 o tetrazol; donde R5 es alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático;(b) R2 es H o alquilo inferior;(c) X es NR6 R7 , OR8 , SR9 , S(O)R9 , ó S(O)2 R9 ; donde R6 , R7 y R8 son independientemente seleccionados del grupo consistente de H, acilo, alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático; y donde R9 es alquilo, eteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático;(d) R3 y R4 son independientemente seleccionados del grupo consistente de H, CH3 y C2 H5 ;(e) Y es NR10 , S, S(O) ó S(O)2 ; donde R10 es H, acilo, alquilo, heteroalquilo, anillo alifático heterocíclico, anillo aromático o anillo eteroaromático.(f) Z es anillo alifático heterocíclico, anillo aromático o anillo heteroaromático; ycualquier isómero óptico, diestereómero, enantiómero de la extructura anterior o una sal farmacéuticamente aceptable o amida biohidrolizable, éster o imida de ellos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5821797P | 1997-09-09 | 1997-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4970731A1 true CO4970731A1 (es) | 2000-11-07 |
Family
ID=22015427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO98051818A CO4970731A1 (es) | 1997-09-09 | 1998-09-09 | Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp |
Country Status (24)
Country | Link |
---|---|
US (1) | US5977173A (es) |
EP (1) | EP1012136B1 (es) |
JP (1) | JP2001515882A (es) |
KR (1) | KR20010023839A (es) |
CN (1) | CN1269786A (es) |
AR (1) | AR013477A1 (es) |
AT (1) | ATE270660T1 (es) |
AU (1) | AU731153B2 (es) |
BR (1) | BR9811774A (es) |
CA (1) | CA2303764C (es) |
CO (1) | CO4970731A1 (es) |
DE (1) | DE69824966T2 (es) |
ES (1) | ES2223141T3 (es) |
HU (1) | HUP0100638A3 (es) |
ID (1) | ID23971A (es) |
IL (1) | IL134839A0 (es) |
NO (1) | NO20001141L (es) |
NZ (1) | NZ503735A (es) |
PE (1) | PE115499A1 (es) |
PL (1) | PL339212A1 (es) |
SK (1) | SK3372000A3 (es) |
TR (1) | TR200000671T2 (es) |
WO (1) | WO1999012895A1 (es) |
ZA (1) | ZA988230B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ513825A (en) | 1999-03-05 | 2001-09-28 | Procter & Gamble | C 16 unsaturated FP-selective prostaglandins analogs |
US6894175B1 (en) * | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
AU776375B2 (en) | 1999-08-04 | 2004-09-09 | Duke University | Novel 2-decarboxy-2-phosphinico prostaglandin F analogs |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
KR100437873B1 (ko) * | 2001-05-08 | 2004-06-26 | 연성정밀화학(주) | 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질 |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US20060135609A1 (en) | 2004-10-21 | 2006-06-22 | Duke University | Ophthamological drugs |
US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
RU2010121880A (ru) * | 2007-10-31 | 2011-12-10 | Памела ЛИПКИН (US) | Композиции аналогов простагландина и способы лечения состояний, затрагивающих эпителий |
US20100074857A1 (en) * | 2008-09-23 | 2010-03-25 | Pamela Lipkin | Compositions and methods to treat epithelial-related conditions |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
EP2349242B1 (en) | 2008-10-29 | 2018-12-05 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
WO2010077101A2 (ko) | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
US8394826B2 (en) | 2009-05-01 | 2013-03-12 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
NZ628266A (en) | 2009-11-09 | 2016-02-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
EP3811943B1 (en) | 2013-03-15 | 2023-02-22 | Aerie Pharmaceuticals, Inc. | Compound for use in the treatment of ocular disorders |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3776938A (en) * | 1958-05-28 | 1973-12-04 | S Bergstrom | Dihydro-pge1 |
US4011262A (en) * | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
US4024179A (en) * | 1972-11-08 | 1977-05-17 | Pfizer Inc. | Substituted ω-pentanorprostaglandins |
IL50310A (en) * | 1972-11-08 | 1977-08-31 | Pfizer | Dimethyl ketophosphonates |
JPS5720305B2 (es) * | 1973-02-28 | 1982-04-27 | ||
DE2365101A1 (de) * | 1973-12-21 | 1975-07-10 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
DE2460990A1 (de) * | 1974-12-21 | 1976-07-01 | Hoechst Ag | Neue prostaglandin-analoga und verfahren zu ihrer herstellung |
GB1507211A (en) * | 1975-02-14 | 1978-04-12 | Ono Pharmaceutical Co | Prostaglandin analogues |
GB1506817A (en) * | 1975-03-31 | 1978-04-12 | Upjohn Co | Prostaglandins |
DE2517771A1 (de) * | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
US4051238A (en) * | 1976-06-03 | 1977-09-27 | The Upjohn Company | Treatment of genital tract diseases of domestic animals with prostaglandins |
DE2737808A1 (de) * | 1976-08-27 | 1978-03-16 | Pfizer | 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine |
US4206151A (en) * | 1978-12-21 | 1980-06-03 | American Cyanamid Company | 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series |
US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
JP2721414B2 (ja) * | 1988-09-06 | 1998-03-04 | フアーマシア・アンド・アツプジヨン・アー・ベー | 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体 |
US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
CA2030345C (en) * | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
TW249226B (es) * | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
US5302617A (en) * | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
DE4024347A1 (de) * | 1990-07-27 | 1992-01-30 | Schering Ag | Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5332730A (en) * | 1992-10-16 | 1994-07-26 | Allergan, Inc. | Azido derivatives of cyclopentane heptanoic or heptenoic acid |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US5545665A (en) * | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
US6169111B1 (en) * | 1995-06-07 | 2001-01-02 | Alcon Laboratories, Inc. | Conformationally rigid aryl prostaglandins for use in glaucoma therapy |
WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
DE69714698T2 (de) * | 1996-06-10 | 2002-12-05 | Sucampo Ag, Zug | Endothelin-antagonisten |
DE69714274T3 (de) * | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
AU5436198A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
US6353014B1 (en) * | 1996-11-12 | 2002-03-05 | Alcon Laboratories, Inc. | 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension |
CA2293325C (en) * | 1997-05-09 | 2008-09-02 | The Mount Sinai School Of Medicine Of The City University Of New York | 8-iso-prostaglandins for glaucoma therapy |
-
1998
- 1998-09-04 TR TR2000/00671T patent/TR200000671T2/xx unknown
- 1998-09-04 PL PL98339212A patent/PL339212A1/xx unknown
- 1998-09-04 ES ES98944719T patent/ES2223141T3/es not_active Expired - Lifetime
- 1998-09-04 NZ NZ503735A patent/NZ503735A/en unknown
- 1998-09-04 HU HU0100638A patent/HUP0100638A3/hu unknown
- 1998-09-04 BR BR9811774-2A patent/BR9811774A/pt not_active IP Right Cessation
- 1998-09-04 WO PCT/US1998/018339 patent/WO1999012895A1/en not_active Application Discontinuation
- 1998-09-04 JP JP2000510707A patent/JP2001515882A/ja not_active Withdrawn
- 1998-09-04 CA CA002303764A patent/CA2303764C/en not_active Expired - Lifetime
- 1998-09-04 CN CN98808990A patent/CN1269786A/zh active Pending
- 1998-09-04 DE DE69824966T patent/DE69824966T2/de not_active Expired - Lifetime
- 1998-09-04 AU AU92193/98A patent/AU731153B2/en not_active Expired
- 1998-09-04 US US09/148,006 patent/US5977173A/en not_active Expired - Lifetime
- 1998-09-04 KR KR1020007002515A patent/KR20010023839A/ko not_active Application Discontinuation
- 1998-09-04 IL IL13483998A patent/IL134839A0/xx unknown
- 1998-09-04 EP EP98944719A patent/EP1012136B1/en not_active Expired - Lifetime
- 1998-09-04 SK SK337-2000A patent/SK3372000A3/sk unknown
- 1998-09-04 AT AT98944719T patent/ATE270660T1/de not_active IP Right Cessation
- 1998-09-04 ID IDW20000639A patent/ID23971A/id unknown
- 1998-09-08 AR ARP980104479A patent/AR013477A1/es unknown
- 1998-09-08 PE PE1998000843A patent/PE115499A1/es not_active Application Discontinuation
- 1998-09-09 CO CO98051818A patent/CO4970731A1/es unknown
- 1998-09-09 ZA ZA988230A patent/ZA988230B/xx unknown
-
2000
- 2000-03-06 NO NO20001141A patent/NO20001141L/no unknown
Also Published As
Publication number | Publication date |
---|---|
TR200000671T2 (tr) | 2000-07-21 |
HUP0100638A3 (en) | 2002-12-28 |
EP1012136B1 (en) | 2004-07-07 |
NO20001141D0 (no) | 2000-03-06 |
JP2001515882A (ja) | 2001-09-25 |
PL339212A1 (en) | 2000-12-04 |
IL134839A0 (en) | 2001-05-20 |
CA2303764A1 (en) | 1999-03-18 |
ES2223141T3 (es) | 2005-02-16 |
EP1012136A1 (en) | 2000-06-28 |
ID23971A (id) | 2000-06-14 |
NZ503735A (en) | 2001-05-25 |
SK3372000A3 (en) | 2000-10-09 |
CN1269786A (zh) | 2000-10-11 |
NO20001141L (no) | 2000-05-04 |
DE69824966D1 (de) | 2004-08-12 |
HUP0100638A2 (hu) | 2001-07-30 |
US5977173A (en) | 1999-11-02 |
AU731153B2 (en) | 2001-03-22 |
ZA988230B (en) | 1999-03-09 |
DE69824966T2 (de) | 2005-04-07 |
WO1999012895A1 (en) | 1999-03-18 |
AU9219398A (en) | 1999-03-29 |
KR20010023839A (ko) | 2001-03-26 |
BR9811774A (pt) | 2000-08-29 |
ATE270660T1 (de) | 2004-07-15 |
CA2303764C (en) | 2005-02-15 |
AR013477A1 (es) | 2000-12-27 |
PE115499A1 (es) | 2000-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4970731A1 (es) | Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp | |
CO4970733A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utiles como agonistas fp | |
CO4970730A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp | |
AR004493A1 (es) | Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen. | |
DK0889889T3 (da) | Piperazin- og piperidinforbindelser | |
PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
ATE177080T1 (de) | Indol derivate zur behandlung von migräne | |
BG97201A (bg) | Цис-2,3,3а,4,5,9в-хексахидро-1н-бензо(е)- индолови производни | |
UA43338C2 (uk) | Похідні бензолу | |
AR002715A1 (es) | Derivados de piperazina y piperazinona heterociclos substituidos particularmente utiles como antagonistas de los receptores de taquikinina,composicion farmaceutica que incluye uno de dichos derivados, uso de dichos compuestos en la preparacion de las composiciones y procedimiento para la preparacion de los derivados | |
CO4940478A1 (es) | Derivados de 1-(2-acilimidazol-1-ilalquil) quinuclidino | |
PT728748E (pt) | Novos derivados da benzodiazepina | |
DE60113145D1 (de) | Selektive glucocorticoid rezeptor agonisten | |
ZA974886B (en) | Novel dibenzo-oxazepine and -dioxepine derivatives. | |
AR023528A1 (es) | Derivados de ciclobuten-3,4-diona, su preparacion y su aplicacion en terapeutica | |
AR016689A1 (es) | Oximas sustituidas. | |
NO20021162D0 (no) | 5-aminoalkyl og 5-aminokarbonyl-substituerte indoler | |
AR008920A1 (es) | Proceso para la preparacion de los derivados de 2-amino-2-imidaxolina, guanidina, y 2-amino-3,4,5,6-tetrahidropiridimina | |
YU179991A (sh) | Racemski ili optički izohinolinski derivati | |
ES2162731B1 (es) | Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas. | |
HUP0300100A2 (en) | Peptide betha-turn mimetic compounds and processes for making them | |
EA200000162A1 (ru) | Производные индола и 2,3-дигидроиндола, их получение и использование | |
ECSP951498A (es) | Nuevos derivados de pirrocarbazol case ran 4121/15 | |
AR003109A1 (es) | Compuesto con actividad antitumoral importante y toxicidad baja y sal farmaceuticamente aceptable compuesto y composicion farmaceutica que locontiene | |
UY23759A1 (es) | Derivados de amida heterociclica |